SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-341306
Filing Date
2021-11-26
Accepted
2021-11-26 17:22:37
Documents
15
Period of Report
2021-11-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d131581d8k.htm   iXBRL 8-K 28579
2 EX-1.1 d131581dex11.htm EX-1.1 145221
3 EX-5.1 d131581dex51.htm EX-5.1 10309
7 GRAPHIC g131581dsp0001.jpg GRAPHIC 2641
  Complete submission text file 0001193125-21-341306.txt   356322

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA atra-20211126.xsd EX-101.SCH 2892
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20211126_lab.xml EX-101.LAB 18139
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20211126_pre.xml EX-101.PRE 11408
8 EXTRACTED XBRL INSTANCE DOCUMENT d131581d8k_htm.xml XML 3376
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 211452292
SIC: 2836 Biological Products, (No Diagnostic Substances)